Insiders Enjoy CN¥112m Return After Buying Huakang Biomedical Holdings Stock

Insiders who bought Huakang Biomedical Holdings Company Limited (HKG:8622) stock lover the last 12 months are probably not as affected by last week’s 12% loss. After accounting for the recent loss, the CN¥49.0m worth of shares they purchased is now worth CN¥161.2m, suggesting a good return on their investment.

Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Huakang Biomedical Holdings Insider Transactions Over The Last Year

Earlier in the year, Executive Director Xunyong Zhou paid HK$0.13 per share in a HK$17m purchase. Even though the purchase was made at a significantly lower price than the recent price (HK$0.41), we still think insider buying is a positive. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.

Over the last year, we can see that insiders have bought 398.13m shares worth HK$49m. On the other hand they divested 398.10m shares, for HK$49m. Overall, Huakang Biomedical Holdings insiders were net buyers during the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

Check out our latest analysis for Huakang Biomedical Holdings

Huakang Biomedical Holdings is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.

Have Huakang Biomedical Holdings Insiders Traded Recently?

In the last quarter we saw Executive Director Xunyong Zhou spend HK$17m on shares. However that only slightly eclipses the sales, HK$17m worth of sales. Looking at the net result, we don't think these recent trades shed much light on how insiders, as a group, are feeling about the company's prospects.

Insider Ownership

For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. It's great to see that Huakang Biomedical Holdings insiders own 54% of the company, worth about HK$110m. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

So What Do The Huakang Biomedical Holdings Insider Transactions Indicate?

Insider purchases may have been minimal, in the last three months, but there was no selling at all. That said, the purchases were not large. On a brighter note, the transactions over the last year are encouraging. Judging from their transactions, and high insider ownership, Huakang Biomedical Holdings insiders feel good about the company's future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. For instance, we've identified 3 warning signs for Huakang Biomedical Holdings (1 is concerning) you should be aware of.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.